Blue Jet Healthcare shares surged 6.26% to ₹511.55 following the company's strong sequential improvement in quarterly earnings. According to reports from Business Standard, the specialty pharmaceutical and healthcare ingredient company demonstrated resilience despite year-over-year challenges, with the stock movement reflecting investor confidence in the company's operational recovery. This positive momentum represents a significant turnaround for a stock that has fallen 37% over the last 12 months and is down 3% on a year-to-date basis.
On a standalone basis, the company reported a net profit of ₹64.34 crore in Q4 FY26, showing a 60.17% quarter-over-quarter increase but declining 41.56% year-over-year from ₹110 crore. As reported by Business Standard, revenue from operations declined 31.07% YoY to ₹234.67 crore (₹235 crore according to latest reports) due to negligible sales of one molecule in the PI vertical, though it increased 22% QoQ from ₹192.41 crore driven by higher sales of advanced contrast media. The revenue decline was attributed to timing-related order phasing in select PI accounts and customer-side inventory normalization, both of which the company said have now run their course.
According to the company's financial results reported by Business Standard, gross profit stood at ₹132.5 crore in Q4 FY26, declining 29.2% YoY but rising 33% QoQ. Gross margin improved significantly to 56.4% from 51.7% in Q3 FY26, supported by favourable product mix and higher sales of contrast media intermediates. EBITDA stood at ₹71.3 crore, declining 49.1% YoY but increasing 52% QoQ, with EBITDA margin improving to 30.4% from 24.4% in the previous quarter. The latest reports confirm that gross margins improved to 56% from 52% quarter-over-quarter, driven by higher sales of advanced contrast media.
For the full financial year FY26, as reported by Business Standard, net profit declined 18.8% YoY to ₹247.82 crore, while revenue fell 8.03% YoY to ₹947.32 crore. However, the company showed strong cash generation with net cash flow from operating activities improving sharply to ₹334.14 crore in FY26 from ₹45.76 crore in FY25. The board recommended a final dividend of ₹1.2 per equity share for the Financial Year ended March 31, 2026.
According to Business Standard, management maintained that underlying demand visibility remains strong and expects normalization in upcoming quarters. On the cost front, raw material costs declined 43.18% YoY to ₹92.89 crore, while employee expenses increased 15.57% YoY to ₹18.48 crore. Interest costs rose sharply to ₹0.58 crore from ₹0.03 crore a year ago, while depreciation expenses increased 30.51% YoY to ₹6.46 crore.
